{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:29Z","timestamp":1787237609113,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NSFC82272385"],"award-info":[{"award-number":["NSFC82272385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10495-025-02253-3","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T18:52:52Z","timestamp":1770663172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oncogenic and immunological roles of LAMP5 across cancers and its potential utility in bladder cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Zhenni","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemeng","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"1","key":"2253_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2253_CR2","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/ijms26052042","volume":"26","author":"CY Lee","year":"2025","unstructured":"Lee CY, Lee SW, Hsu YC (2025) Drug resistance in late-stage epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients after first-line treatment with tyrosine kinase inhibitors. Int J Mol Sci 26(5):2042","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2253_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41571-022-00676-4","volume":"19","author":"YR Murciano-Goroff","year":"2022","unstructured":"Murciano-Goroff YR, Lito P (2022) The KRYSTAL-1 study of adagrasib\u2014a new trial for KRASG12C-mutated non-small-cell lung cancer. Nat Rev Clin Oncol 19(11):677\u2013678","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2253_CR4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F (2021) Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 32(9):1101\u20131110","journal-title":"Ann Oncol"},{"issue":"10","key":"2253_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C (2020) Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov 19(10):711\u2013736","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"2253_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marm\u00e9 F, Lindemann K et al (2023) Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann Oncol 34(12):1152\u20131164","journal-title":"Ann Oncol"},{"issue":"1","key":"2253_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL (2022) Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther 7(1):331","journal-title":"Signal Transduct Target Ther"},{"key":"2253_CR8","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.ctrv.2024.102751","volume":"127","author":"L Rached","year":"2024","unstructured":"Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F et al (2024) Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations. Cancer Treat Rev 127:102751","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2253_CR9","doi-asserted-by":"publisher","first-page":"e2303175","DOI":"10.1002\/advs.202303175","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhou Y, Yang L, Lei L, He B, Cao J et al (2024) Challenges coexist with opportunities: spatial heterogeneity expression of PD-L1 in cancer therapy. Adv Sci 11(1):e2303175","journal-title":"Adv Sci"},{"issue":"11","key":"2253_CR10","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2019.07.006","volume":"14","author":"D Kazdal","year":"2019","unstructured":"Kazdal D, Endris V, Allg\u00e4uer M, Kriegsmann M, Leichsenring J, Volckmar AL et al (2019) Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts. J Thorac Oncol 14(11):1935\u20131947","journal-title":"J Thorac Oncol"},{"issue":"10","key":"2253_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1741-7007-10-62","volume":"19","author":"S Wilke","year":"2012","unstructured":"Wilke S, Krausze J, B\u00fcssow K (2012) Crystal structure of the conserved domain of the DC lysosomal associated membrane protein: implications for the lysosomal glycocalyx. BMC Biol 19(10):62","journal-title":"BMC Biol"},{"issue":"4","key":"2253_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.seminoncol.2017.10.013","volume":"44","author":"F Alessandrini","year":"2017","unstructured":"Alessandrini F, Pezz\u00e8 L, Ciribilli Y (2017) LAMPs: shedding light on cancer biology. Semin Oncol 44(4):239\u2013253","journal-title":"Semin Oncol"},{"key":"2253_CR13","doi-asserted-by":"publisher","first-page":"1611083","DOI":"10.3389\/pore.2023.1611083","volume":"29","author":"Y Chen","year":"2023","unstructured":"Chen Y, Ma T (2023) LAMP5 may promote MM progression by activating p38. Pathol Oncol Res 29:1611083","journal-title":"Pathol Oncol Res"},{"issue":"38","key":"2253_CR14","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1038\/s41388-025-03513-x","volume":"44","author":"Z Li","year":"2025","unstructured":"Li Z, Liu R, Fang Z, Chen R, Yang D, Li Y et al (2025) LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy. Oncogene 44(38):3553\u20133567","journal-title":"Oncogene"},{"issue":"9","key":"2253_CR15","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/1078-0432.CCR-18-1474","volume":"25","author":"WT Wang","year":"2019","unstructured":"Wang WT, Han C, Sun YM, Chen ZH, Fang K, Huang W et al (2019) Activation of the lysosome-associated membrane protein LAMP5 by DOT1L serves as a bodyguard for MLL fusion oncoproteins to evade degradation in leukemia. Clin Cancer Res 25(9):2795\u20132808","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2253_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10120-022-01284-y","volume":"25","author":"S Umeda","year":"2022","unstructured":"Umeda S, Kanda M, Shimizu D, Nakamura S, Sawaki K, Inokawa Y et al (2022) Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. Gastric Cancer 25(3):558\u2013572","journal-title":"Gastric Cancer"},{"key":"2253_CR17","first-page":"119","volume":"17","author":"P Wu","year":"2024","unstructured":"Wu P, Zhang J, Guo L, Chen B, Xiong L, Du Y (2024) LAMP5, one of four genes related to oxidative stress that predict biochemical recurrence-free survival, promotes proliferation and invasion in prostate cancer. Adv Appl Bioinform Chem 17:119\u2013138","journal-title":"Adv Appl Bioinform Chem"},{"issue":"Suppl 8","key":"2253_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1186\/s12864-018-5193-9","volume":"19","author":"J Martinez-Romero","year":"2018","unstructured":"Martinez-Romero J, Bueno-Fortes S, Mart\u00edn-Merino M, Ramirez de Molina A, De Las RJ (2018) Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling. BMC Genomics 19(Suppl 8):857","journal-title":"BMC Genomics"},{"issue":"9","key":"2253_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-9-3","volume":"8","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P et al (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 8(9):3","journal-title":"Mol Cancer"},{"issue":"5","key":"2253_CR20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-11-2271","volume":"18","author":"M Riester","year":"2012","unstructured":"Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ et al (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18(5):1323\u20131333","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2253_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152\u2013165","journal-title":"Cancer Cell"},{"issue":"5","key":"2253_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"J David McConkey","year":"2016","unstructured":"David McConkey J, Choi W, Shen Y, Lee IL, Porten S, Surena Matin F et al (2016) A prognostic gene expression signature in the molecular classification of chemotherapy-na\u00efve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 69(5):855\u2013862","journal-title":"Eur Urol"},{"issue":"12","key":"2253_CR23","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl G, Lauss M, L\u00f6vgren K, Chebil G, Gudjonsson S, Veerla S et al (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18(12):3377\u20133386","journal-title":"Clin Cancer Res"},{"issue":"15 Pt 1","key":"2253_CR24","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-07-0109","volume":"13","author":"AB Als","year":"2007","unstructured":"Als AB, Dyrskj\u00f8t L, von der Maase H, Koed K, Mansilla F, Toldbod HE et al (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13(15 Pt 1):4407\u20134414","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2253_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM et al (2021) Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. British J Cancer 125(9):1251\u20131260","journal-title":"British J Cancer"},{"issue":"1","key":"2253_CR26","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ et al (2019) DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun 10(1):4278","journal-title":"Nat Commun"},{"issue":"4","key":"2253_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS et al (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171(4):934-949.e16","journal-title":"Cell"},{"issue":"4","key":"2253_CR28","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH et al (2018) The immune landscape of cancer. Immunity 48(4):812-830.e14","journal-title":"Immunity"},{"key":"2253_CR29","doi-asserted-by":"crossref","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O et al (2021) Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39(6):845\u2013865.e7","DOI":"10.1016\/j.ccell.2021.04.014"},{"issue":"7693","key":"2253_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548","journal-title":"Nature"},{"key":"2253_CR31","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Commun 4:2612","journal-title":"Nature Commun"},{"key":"2253_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711:243\u2013259","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2253_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12967-024-05109-7","volume":"22","author":"Y Ma","year":"2024","unstructured":"Ma Y, Jin J, Xue Z, Zhao J, Cai W, Zhang W (2024) Integrated multi-omics analysis and machine learning developed a prognostic model based on mitochondrial function in a large multicenter cohort for gastric cancer. J Transl Med 22(1):381","journal-title":"J Transl Med"},{"key":"2253_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/bs.mie.2019.05.056","volume":"636","author":"C Plattner","year":"2020","unstructured":"Plattner C, Finotello F, Rieder D (2020) Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. Methods Enzymol 636:261\u2013285","journal-title":"Methods Enzymol"},{"issue":"7269","key":"2253_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462(7269):108\u2013112","journal-title":"Nature"},{"key":"2253_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-0716-0327-7_19","volume":"2120","author":"D Aran","year":"2020","unstructured":"Aran D (2020) Cell-type enrichment analysis of bulk transcriptomes using xCell. Methods Mol Biol 2120:263\u2013276","journal-title":"Methods Mol Biol"},{"issue":"21","key":"2253_CR37","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS et al (2017) TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res 77(21):e108\u2013e110","journal-title":"Cancer Res"},{"issue":"1","key":"2253_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218","journal-title":"Genome Biol"},{"issue":"6","key":"2253_CR39","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","volume":"26","author":"G Monaco","year":"2019","unstructured":"Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carr\u00e9 C et al (2019) RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell Rep 26(6):1627-1640.e7","journal-title":"Cell Rep"},{"issue":"24","key":"2253_CR40","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","volume":"79","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2019","unstructured":"Jim\u00e9nez-S\u00e1nchez A, Cast O, Miller ML (2019) Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res 79(24):6238\u20136246","journal-title":"Cancer Res"},{"issue":"7","key":"2253_CR41","doi-asserted-by":"publisher","first-page":"1902880","DOI":"10.1002\/advs.201902880","volume":"7","author":"YR Miao","year":"2020","unstructured":"Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H et al (2020) ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci 7(7):1902880","journal-title":"Adv Sci"},{"issue":"23","key":"2253_CR42","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1158\/0008-5472.CAN-18-0689","volume":"78","author":"L Xu","year":"2018","unstructured":"Xu L, Deng C, Pang B, Zhang X, Liu W, Liao G et al (2018) TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res 78(23):6575\u20136580","journal-title":"Cancer Res"},{"issue":"5","key":"2253_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401\u2013404","journal-title":"Cancer Discov"},{"issue":"7","key":"2253_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2017.76.8770","volume":"36","author":"CE Steuer","year":"2018","unstructured":"Steuer CE, Ramalingam SS (2018) Tumor mutation burden: leading immunotherapy to the era of precision medicine? J Clin Oncol 36(7):631\u2013632","journal-title":"J Clin Oncol"},{"issue":"2","key":"2253_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN et al (2018) Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173(2):338-354.e15","journal-title":"Cell"},{"issue":"11","key":"2253_CR46","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.omtn.2018.03.003","volume":"1","author":"H Jin","year":"2018","unstructured":"Jin H, Sun W, Zhang Y, Yan H, Liufu H, Wang S et al (2018) MicroRNA-411 downregulation enhances tumor growth by upregulating MLLT11 expression in human bladder cancer. Mol Ther Nucleic Acids 1(11):312\u2013322","journal-title":"Mol Ther Nucleic Acids"},{"issue":"8","key":"2253_CR47","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","volume":"25","author":"AH Nassar","year":"2019","unstructured":"Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM et al (2019) Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin Cancer Res 25(8):2458\u20132470","journal-title":"Clin Cancer Res"},{"issue":"7492","key":"2253_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Network TCGAR","year":"2014","unstructured":"Network TCGAR (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315","journal-title":"Nature"},{"issue":"3","key":"2253_CR49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3):540-556.e25","journal-title":"Cell"},{"issue":"6","key":"2253_CR50","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","volume":"68","author":"JP Sfakianos","year":"2015","unstructured":"Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH et al (2015) Genomic characterization of upper tract urothelial carcinoma. Eur Urol 68(6):970\u2013977","journal-title":"Eur Urol"},{"issue":"6","key":"2253_CR51","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","volume":"16","author":"TPS Perera","year":"2017","unstructured":"Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T et al (2017) Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther 16(6):1010\u20131020","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2253_CR52","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3390\/cancers14071795","volume":"14","author":"J Thomas","year":"2022","unstructured":"Thomas J, Sonpavde G (2022) Molecularly targeted therapy towards genetic alterations in advanced bladder cancer. Cancers (Basel) 14(7):1795","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2253_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.annonc.2023.11.006","volume":"35","author":"GP Sonpavde","year":"2024","unstructured":"Sonpavde GP, Subbiah V (2024) Unlocking precision oncology with FGFR inhibition in urothelial carcinoma. Ann Oncol 35(2):150\u2013153","journal-title":"Ann Oncol"},{"issue":"5293","key":"2253_CR54","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","volume":"274","author":"CJ Sherr","year":"1996","unstructured":"Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672\u20131677","journal-title":"Science"},{"issue":"3","key":"2253_CR55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153\u2013166","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2253_CR56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.kjms.2014.05.003","volume":"30","author":"CH Yang","year":"2014","unstructured":"Yang CH, Wu CC, Chen WT, Chai CY, Yang SF (2014) Expressions of p16 and p27 in urothelial carcinoma and their prognostic value. Kaohsiung J Med Sci 30(9):453\u2013458","journal-title":"Kaohsiung J Med Sci"},{"key":"2253_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian A, Ahmadi Y, Yousefi B (2016) Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair 42:63\u201371","journal-title":"DNA Repair"},{"issue":"2","key":"2253_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nm0297-227","volume":"3","author":"C Catzavelos","year":"1997","unstructured":"Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C et al (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3(2):227\u2013230","journal-title":"Nat Med"},{"issue":"16","key":"2253_CR59","first-page":"3381","volume":"57","author":"V Esposito","year":"1997","unstructured":"Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG et al (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57(16):3381\u20133385","journal-title":"Cancer Res"},{"issue":"9","key":"2253_CR60","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1054\/bjoc.2000.1736","volume":"84","author":"T Kamai","year":"2001","unstructured":"Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI (2001) Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 84(9):1242\u20131251","journal-title":"Br J Cancer"},{"key":"2253_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12935-015-0256-3","volume":"15","author":"M Sha","year":"2015","unstructured":"Sha M, Ye J, Luan ZY, Guo T, Wang B, Huang JX (2015) Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer. Cancer Cell Int 15:101","journal-title":"Cancer Cell Int"},{"key":"2253_CR62","first-page":"1293","volume":"9","author":"CX Yuan","year":"2015","unstructured":"Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D et al (2015) Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K\/Akt\/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther 9:1293\u20131318","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2253_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1044-579X(02)00098-6","volume":"13","author":"J Bloom","year":"2003","unstructured":"Bloom J, Pagano M (2003) Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 13(1):41\u201347","journal-title":"Semin Cancer Biol"},{"issue":"5224","key":"2253_CR64","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1126\/science.7624798","volume":"269","author":"M Pagano","year":"1995","unstructured":"Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V et al (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269(5224):682\u2013685","journal-title":"Science"},{"issue":"18","key":"2253_CR65","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.2174\/13816128113199990300","volume":"19","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Sun Y (2013) Cullin-RING ligases as attractive anti-cancer targets. Curr Pharm Des 19(18):3215\u20133225","journal-title":"Curr Pharm Des"},{"issue":"21","key":"2253_CR66","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1101\/gad.1255304","volume":"18","author":"J Jin","year":"2004","unstructured":"Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW (2004) Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18(21):2573\u20132580","journal-title":"Genes Dev"},{"issue":"11","key":"2253_CR67","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1111\/febs.15585","volume":"288","author":"Y Bi","year":"2021","unstructured":"Bi Y, Cui D, Xiong X, Zhao Y (2021) The characteristics and roles of \u03b2-TrCP1\/2 in carcinogenesis. FEBS J 288(11):3351\u20133374","journal-title":"FEBS J"},{"issue":"39","key":"2253_CR68","doi-asserted-by":"publisher","first-page":"26759","DOI":"10.1074\/jbc.M802160200","volume":"283","author":"S Wei","year":"2008","unstructured":"Wei S, Yang HC, Chuang HC, Yang J, Kulp SK, Lu PJ et al (2008) A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J Biol Chem 283(39):26759\u201326770","journal-title":"J Biol Chem"},{"issue":"13","key":"2253_CR69","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1016\/j.celrep.2018.08.076","volume":"24","author":"I Mavrommati","year":"2018","unstructured":"Mavrommati I, Faedda R, Galasso G, Li J, Burdova K, Fischer R et al (2018) \u03b2-TrCP- and casein kinase II-mediated degradation of cyclin f controls timely mitotic progression. Cell Rep 24(13):3404\u20133412","journal-title":"Cell Rep"},{"issue":"18","key":"2253_CR70","doi-asserted-by":"publisher","first-page":"6279","DOI":"10.1073\/pnas.0501873102","volume":"102","author":"Y Kanemori","year":"2005","unstructured":"Kanemori Y, Uto K, Sagata N (2005) Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc Natl Acad Sci U S A 102(18):6279\u20136284","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6962","key":"2253_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature02082","volume":"426","author":"L Busino","year":"2003","unstructured":"Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV et al (2003) Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426(6962):87\u201391","journal-title":"Nature"},{"issue":"6","key":"2253_CR72","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1534-5807(03)00154-0","volume":"4","author":"D Guardavaccaro","year":"2003","unstructured":"Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M et al (2003) Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4(6):799\u2013812","journal-title":"Dev Cell"},{"issue":"13","key":"2253_CR73","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1073\/pnas.0307700101","volume":"101","author":"N Watanabe","year":"2004","unstructured":"Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T et al (2004) M-phase kinases induce phospho-dependent ubiquitination of somatic wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A 101(13):4419\u20134424","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2253_CR74","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/sj.onc.1207389","volume":"23","author":"SY Fuchs","year":"2004","unstructured":"Fuchs SY, Spiegelman VS, Kumar KGS (2004) The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23(11):2028\u20132036","journal-title":"Oncogene"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02253-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:02:09Z","timestamp":1774080129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02253-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02253-3","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no competing interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of Wenzhou Medical University. All the animal experiments performed in the present study were approved by the regulation of the experimental animal ethics committee of Wenzhou Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"65"}}